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a b s t r a c t 
Due to the physicochemical properties of bile acids/salts ( i.e ., hydrophobic and ionizable), the application of 
reverse-phase liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based methods are ideally suited 
for the measurement of these compounds in a host of microbiologically-relevant matrices. Here, we provide a 
detailed bioanalytical protocol that contains several modifications of a method previously described by Wegner 
et al. [1] . Briefly, this modified method exhibits the following advantages for the measurement of cholic acid 
(CA), taurocholic acid (TCA), and deoxycholic acid (DCA) in microbiome-relevant sample matrices: i) fecal sample 
processing has been streamlined by the elimination of lyophilization and manual homogenization steps; ii) the 
Sciex 6500 QTRAP hybrid triple-quadrupole/linear ion trap mass spectrometer has sufficient sensitivity to perform 
the measurement of bile acids/salts in negative ion mode – ammonium adducts of bile acids/salts are not required 
for detection; and, iii) assay throughput has been boosted by more than 5-fold by shortening the chromatographic 
duty cycle of a single sample injection from 45 min to 8.4 min. Recently, the method was used to perform 508 
sequential injections (72 calibration standards, 52 blank-internal standard sample, and 368 MiniBioReactor Array 
(MBRA)-derived samples) from four separate batches over a 4-day time period. 
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Specifications Table 
Subject Area: Immunology and Microbiology 
More specific subject area: Microbiome-related research projects 
Protocol name: Measurement of bile acids/salts in microbiome relevant matrices by LC-MS/MS 
Reagents/tools: Materials 
Optima LC/MS-grade water, methanol, and acetonitrile, and ACS reagent-grade, 
absolute ethanol (200 proof) were from Thermo Fisher Scientific (Waltham, 
MA, USA). Ammonium formate (99%), phosphate buffered saline (PBS), and 
dimethyl sulfoxide (DMSO) were from Millipore Sigma (Billerica, MA, USA). The 
authentic reference materials for sodium cholic acid (CA) and sodium 
deoxycholic acid (DCA) were from Thermo Fisher Scientific, and sodium 
taurocholic acid (TCA) was from Millipore Sigma. Authentic D 4 -cholic acid 
(D 4 –CA) and D 4 -deoxycholic acid (D 4 -DCA) Internal Standard (IS) reference 
materials were purchased from CDN Isotopes (Pointe-Claire, Quebec, Canada). 
Polyvinyl difluoride (PVDF) membrane filter plates with 0.2 μm pores were 
from Thermo Fisher Scientific. High-Performance Liquid Chromatography 
(HPLC) separations were performed using a Raptor C18 (2.7 μm superficially 
porous silica particle (SPP), 100 mm (L) x 2.1 mm (ID), 90 A˚ pore size; Cat 
#9304A12) analytical column and an Ultra C18 (5.0 μm silica, 10 mm 
(L) x 2.1 mm (ID), 100 A˚ pore size; Cat #917450212) guard column from Restek 
(Bellefonte, PA, USA). MiniBioReactor Array (MBRA) devices were constructed 
and used as described previously [11] . 
Biological Materials 
The custom bioreactor medium used for this study has been described 
previously [11] . The protocols for the harvesting and processing of bacterial 
cells from human fecal communities used for this study were described 
previously [11] . The protocols for the collection and processing of mouse fecal 
pellets used for this study were described previously [12] . 
HPLC-tandem mass spectrometry (LC-MS/MS) System 
The method was developed on an LC-MS/MS system comprised of the 
following components: i) a Genius 3031 nitrogen generator by Peak Scientific 
(Inchinnan, Scotland, UK); ii) a Security Plus uninterruptable power supply by 
Powervar (Tustin, CA, USA); iii) a Nexera X2 MP HPLC system by Shimadzu 
(Kyoto, Japan); iv) a Sciex 6500 QTRAP hybrid triple-quadrupole/linear ion trap 
mass spectrometer by Danaher (Washington, DC, USA); and, v) a Dell Optiplex 
XE2 personal computer that has been configured for LC-MS/MS instrument 
control. 
Experimental design: This method provides a detailed description of the materials, equipment, and 
methods necessary for performing LC-MS/MS-based quantitative bioanalysis of 
the CA, TCA, and DCA content of sample matrices pertinent to understanding 
host-microbiome interactions. 
Trial registration: N/A 
Ethics: N/A 
Value of the Protocol: Advantages of this method include: 
1) Bile acids/salts are multifunctional compounds of great interest to the 
microbiome-based research community. 
2) LC-MS/MS-based methods can measure the bile acid/bile salt content in 
bioreactor-derived broth media and stool samples 
3) The method can be considered high-throughput – we are able to process up 
to 192 MiniBioReactor Array (MBRA) or mouse fecal samples per 8 h day, and 
can perform the instrumental analysis of these samples in a 36 h timeframe. 
∗Description of protocol: [This protocol contains refined extraction, chromatographic, and MS/MS procedures that enhance 
the analytical throughput of an existing quantitative LC-MS/MS-based bile acid/salt method [1] . The method modifications described 
herein were necessary to accommodate the large sample counts associated with ongoing microbiome projects supported by the Texas 
Children’s Microbiome Center–Mass Spectrometry Laboratory (TCMC-MSL). The procedural modifications yielded the following method 
improvements: i) the acquisition duty cycle was reduced from 45 min to 8.4 mins per sample; ii) the processing rate was increased 
to 192 samples per 8 h day; and, iii) chromatographic data for the deprotonated precursor ions of the bile acids/salts were measured 
directly using the negative ionization mode of a Sciex 6500 QTRAP MS system, rather than measuring the ammoniated adducts of 
bile acids/salts in positive ionization mode as previously reported [1] . ] 
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Biochemical background 
In the human liver, primary bile acids chenodeoxycholic acid (CDCA) and cholic acid (CA) are 
formed by catabolism of cholesterol [ 2 , 3 ], and are conjugated to glycine and taurine to form the 
hydrophilic bile salts glycocholic acid (GCA) and glycochenodeoxycholic acid (GCDCA), and taurocholic 
acid (TCA) and taurochenodeoxycholic acid (TCDCA), respectively ( Figure 1 )[ 4 , 5 ]. After formation, bile 
salts enter the enterohepatic cycle where they are: i) exported with other hydrophobic components 
to form bile in the gall bladder [6] ; ii) secreted into the duodenum where they aid in the absorption 
and digestion of hydrophobic dietary components; and, iii) are reabsorbed (~95% of the pool) from the 
chyme in the distal ileum and are transported back to the liver via the portal vein thus completing 
a single revolution of the enterohepatic cycle [6] . In the human gut, a small proportion (~5%) of 
the bile salt pool undergoes microbiota-mediated deconjugation of glycine and taurine to reform 
the hydrophobic, cytotoxic, and potentially antimicrobial primary bile acids CDCA and CA [ 7 –9 ], and 
these compounds may be metabolized further to the secondary bile acids, deoxycholic acid (DCA) and 
lithocholic acid (LCA) by microbiota in the large bowel [10] . 
Solution preparations 
Internal standard (IS) solution preparations 
1. Individual Internal Standard (IS) Stock Solutions for D 4 -cholic acid (D 4 –CA) and D 4 -deoxycholic 
acid (D 4 -DCA) are each prepared at a concentration of ~10 mg/mL in Optima LC/MS-grade water 
(grade of water used throughout the protocol), and in a solution of 1:2 dimethyl sulfoxide: 
water, respectively. These solutions are stored frozen at −80 °C while not in use. Note: Free 
D 4 -DCA is relatively water insoluble, therefore it may be necessary to use a combination of vortex- 
mixing (at 20 0 0 RPM for 5 min) and gentle heating (at 70 °C for 1 min ) in a block heater to 
re-solubilize the bile acid/salt content in the freshly thawed stock solution preparations. 
2. A Combined IS Intermediate Solution is prepared by diluting appropriate volumes of the D 4 –CA 
and D 4 -DCA IS Stock Solutions in an appropriate volume of 1:1 methanol: water solution to 
yield a concentration of 500 ng/mL for each compound in the combined solution. This solution 
is refrigerated at + 4 °C while not in use. 
3. A Working IS-A (WIS-A) Solution is prepared by diluting a volume of Combined IS Intermediate 
Solution in an equal volume of 1:1 methanol: water solution yielding a concentration of 
250 ng/mL for each IS component (D 4 –CA and D 4 -DCA). This solution is refrigerated at + 4 °C 
while not in use, and is discarded after 1 week of storage. Note: This solution is used as the 
diluent for all microbiome samples prior to analysis. 
4. A Working IS-B (WIS-B) Solution is prepared by diluting a 9 mL volume of the WIS-A Solution 
with a 1 mL volume of 1:1 methanol: water solution yielding a concentration of 225 ng/mL 
for each IS component (D 4 –CA and D 4 -DCA). This solution is refrigerated at + 4 °C while not 
in use, and is discarded after 1 week of storage. Note: This solution is used as the diluent in the 
preparation of the CA, DCA, and TCA containing Working Analyte Solution, and the serially-diluted 
LC-MS/MS calibration standards. 
Analyte solution preparations 
1. Individual Analyte Stock Solutions for CA, DCA, and TCA are each prepared at a concentration 
of ~100 mg/mL in water. These solutions are stored frozen at −80 °C while not in use. Note: 
sodium salts of bile acids are readily water soluble, but it may still be necessary to re-solubilize 
the bile acid/salt content in the stock solutions. A combination of vortex-mixing (at 20 0 0 RPM for 
5 min) and gentle heating (at 70 °C for 1 min ) may be used to re-solubilize insoluble bile acid/salt 
material. 
2. A Combined Analyte Intermediate Solution is prepared by diluting appropriate volumes of 
the CA, DCA, and TCA Analyte Stock Solutions in an appropriate volume of water to yield a 
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Table 1 
Serial dilution scheme for the preparation of the bile acid/salt Calibrators. 
Calibrator CA, DCA, and TCA 
concentration in each 
Calibrator (ng/mL) 
Source Solution Volume of 
Source Solution 
(μL) 
Volume of 
Working IS-B 
Solution (μL) 
F 10 0 0 Working Analyte Solution 10 990 
E 250 F 100 300 
D 62.5 E 100 300 
C 15.6 D 100 300 
B 3.90 C 100 300 
A 0.977 B 100 300 
concentration of 10.0 mg/mL for each compound in the combined solution. This solution is 
sub-aliquotted at 100 μL volumes and stored frozen at −80 °C while not in use. 
3 A Working Analyte Solution is prepared by diluting an appropriate volume of the Combined 
Analyte Intermediate Solution in an appropriate volume of the WIS-B Solution to yield a 
concentration of 100 μg/mL for each analyte component (CA, DCA, and TCA). This solution is 
refrigerated at + 4 °C while not in use, and is discarded after 1 week of storage. 
4. The LC-MS/MS calibration standards (Calibrators) are prepared by serial dilution using the 
Working Analyte Solution as the primary source solution and the WIS-B solution as the diluent 
(See Table 1 ). These Calibrators are refrigerated at + 4 °C while not in use, and are discarded 
after 1 week of storage. 
Microbiome sample preparation, shipment, and storage and handling conditions 
Bioreactor sample collection, filter-sterilization, and extraction procedures 
Bacterial cells from human fecal communities are grown in the bioreactor medium contained in 
the MBRA devices [11] . Bioreactor medium contains bovine bile as a source of bile salts. Samples are 
removed from communities and cells are pelleted by centrifugation at 30 0 0 g for 5 min. Clarified 
supernatants are filtered through 0.2 μm polyvinyl difluoride (PVDF) membrane filter plates by 
centrifugation at 200 g for 5 min. Filtered samples are stored frozen at −80 °C while awaiting 
shipment to the Texas Children’s Microbiome Center Mass Spectrometry Laboratory (TCMC-MSL). 
Mouse stool collection, filter-sterilization, and extraction procedures 
Fecal samples are collected from human microbiota associated mice and stored at −80 °C [12] . 
Fecal pellets (30–60 mg) are fully resuspended in a 250 μL volume of phosphate buffered saline 
(PBS), and are centrifuged at 20,0 0 0 g for 1 min. The clarified supernatant is transferred to a new 
tube. Decanted fecal material is resuspended in a 250 μL volume of absolute ethanol (200 proof). 
The ethanolic samples are centrifuged at 20,0 0 0 g for 1 min. Equal volumes of the clarified ethanolic 
and PBS supernatants are combined and filtered through 0.2 μM PVDF membrane filter plates by 
centrifugation at 200 g for 5 min. Filtered samples are stored frozen at −80 °C while awaiting 
shipment to the TCMC-MSL. 
Long-term sample storage and handling 
1. Samples (bioreactor media or stool extracts) that are generated offsite are shipped to the TCMC- 
MSL on dry ice, and upon receipt are transferred immediately into a −80 °C freezer for storage 
until further processing and analysis may be performed. Samples that are generated in the 
TCMC are filter-sterilized if needed, and are then transferred to a −80 °C freezer as soon as 
possible. 
2. All microbiome-derived samples are thawed at ambient temperature on the laboratory 
benchtop. 
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3. If samples are provided in 96-well plates, then the entire sample volume contained in each 
well is transferred to individual 0.6 or 1.5 mL Eppendorf tubes, and processed further according 
to the following protocols. All samples are vortex-mixed for 2 min using a multi-tube vortexer. 
Stool sample extracts are centrifuged at 10,0 0 0 g for 10 min to settle the debris prior to sample 
aliquoting and dilution. After sample processing has been completed for the entire batch, the 
residual sample volumes contained in the Eppendorf tubes are stored frozen at −80 °C pending 
re-analysis. 
Sample dilution procedures 
10 0 0-fold sample dilutions for MBRA-derived bioreactor media samples 
1. For this particular study, it was determined that a 10 0 0-fold dilution was suitable for the levels 
of CA and DCA contained in the samples. Dilution factor suitability should be assessed for each 
new study prior to sample analysis. 
2. A 100-fold primary dilution is performed by mixing a 10 μL volume of the undiluted bioreactor 
sample in a 990 μL volume of a 1:1 methanol: water solution. The diluted samples are then 
vortex-mixed for 15 s. 
3. A secondary sample dilution is performed directly in a polypropylene autosampler injection 
vial by mixing a 10 μL volume of the 100-fold diluted bioreactor sample in 90 μL of the WIS-A 
Solution for an overall dilution factor of 10 0 0-fold. The diluted sample is then vortex-mixed for 
15 s, and a 5 μL volume of sample is injected onto the LC-MS/MS system. Note: The 10% dilution 
of the WIS-A solution during sample preparation is accounted for in the preparation of the WIS-B IS 
solution that is used in the preparation of the calibrators. 
10-fold sample dilutions for stool (CA, DCA, and TCA) and MBRA-derived bioreactor (TCA only) samples 
1. For this study, it was determined that a 10-fold dilution was suitable for the levels of TCA 
contained in the MBRA-derived bioreactor samples, and for the CA, DCA, and TCA contained in 
the mouse fecal samples. Dilution factor suitability should be assessed for each new study prior 
to sample analysis. 
2. A 10-fold dilution is performed directly in a polypropylene autosampler injection vial by mixing 
a 10 μL volume of the undiluted bioreactor/stool extract sample in 90 μL of the WIS-A Solution. 
The diluted sample is then vortex-mixed for 15 s, and a 5 μL volume of sample is injected onto 
the LC-MS/MS system. Note: The 10% dilution of the WIS-A solution during sample preparation is 
accounted for in the preparation of the WIS-B IS solution that is used in the preparation of the 
calibrators. 
LC-MS/MS method details 
Mobile phase and needlewash solution preparations 
1. The Mobile Phase A (MPA) Solution is prepared by dissolving 0.631 g of ammonium formate in 
1 L of water in a 1 L HPLC solvent reservoir bottle. The MPA Solution is swirled vigorously to 
ensure complete dissolution of the salt, and is stored well-closed at ambient room temperature 
while not in use, and the solution is discarded after 1 month. 
2. The Mobile Phase B (MPB) Solvent is pure Optima LC/MS-grade acetonitrile and is stored well- 
closed at ambient room temperature while not in use. The pure solvent does not expire. 
3. The Needlewash (NW) Solution is prepared by mixing equal parts of water and Optima LC/MS- 
grade methanol in an HPLC solvent reservoir bottle. The NW Solution swirled vigorously to 
ensure complete mixing, is degassed via sonication, and is stored well-closed at ambient room 
temperature while not in use. This solution does not expire. 
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Fig. 1. Molecular structure, chemical formula, and molar mass for host-derived taurocholic acid (TCA), and microbiota-derived 
cholic acid (CA) and deoxycholic acid (DCA) contained in fecal or bioreactor-derived broth media samples. [7] 
Chromatographic method 
1. Reverse-phase chromatography is performed using a Raptor C18 (2.7 μm SPP particles, 100 mm 
(L) x 2.1 mm (ID), 90 A˚ pore size; Cat #9304A12) analytical column with an Ultra C18 (5.0 μm 
silica, 10 mm (L) x 2.1 mm (ID) mm, 100 A˚ pore size; Cat #917450212) guard column installed. 
2. The needle rinse program on the Nexera X2 MP Autosampler is specified to perform external 
rinsing only both before and after aspiration of sample using 500 μL of NW Solution each time. 
3. The chromatographic method includes a column temperature of 50 °C, an autosampler tray 
temperature of 15 °C, a mobile phase flowrate of 0.30 mL/min, and a gradient elution program 
specified as follows: 0–4.50 min, 5–90% MPB; 4.50–5.50 min, 90% MPB; 5.50–5.60 min, 90% −5% 
MPB; 5.60–8.00 min, 5% MPB; with an overall cycle time of 8.4 min per acquisition, and an 
operational back pressure of ~220 0 psi at initial conditions. The 650 0 QTRAP divert valve was 
enabled and specified to divert the chromatographic eluate according to the following program: 
0–1.00 min, divert to waste (position B); 1.0 0–8.0 0 min, divert to MS source (position A); 8:00–
8.40 min, divert to waste (Position B). 
4. The retention times have typically been 3.1 min for TCA, 3.6 min for CA, and 4.25 min for DCA 
( Fig. 2 ). 
Column efficiency characterization 
The column efficiency characterization for the Raptor C18 analytical and Ultra C18 guard column 
combination was performed by computing the pertinent experimental parameters from a mid-level 
calibration standard (Calibrator D – prepared at 62.5 ng/mL for CA, DCA, and TCA, and 225 ng/mL 
for the IS compounds, D 4 –CA and D 4 -DCA) using previously described methods [13] . Briefly, the 
height equivalent to a theoretical plate (HETP; Eq (1) ) and the number of theoretical plates per 
meter (N/m; Eq (2) ) were calculated using the following experimental parameters for each analyte 
and IS compound: i) full-width at ½ max for the chromatographic peaks ( W 1/2 ) in minutes; ii) the 
chromatographic retention time ( τ R ) in minutes; and, iii) the column length (L) specified in the units 
of cm for the computation of HETP ( Eq. (1) ), and in the units of m for N/m ( Eq. (2) ). All experimental 
parameters used to perform the column efficiency characterization have been tabulated in Table 2 
below. 
HET P 
(
cm 
plate 
)
= 
(
W 1 / 2 
)2 ∗ L ( cm ) 
5 . 54 ∗ ( τR ) 2 
(1) 
plates per meter 
(
N 
m 
)
= 5 . 54 ∗ ( τR ) 
2 
(
W 1 / 2 
)2 ∗ L ( m ) 
(2) 
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Fig. 2. (A-D) Extracted-Ion Chromatograms (XICs) for a calibration standard that contained 62.5 ng/mL of taurocholate (A), 
cholate (B), deoxycholate (C), and 225 ng/mL for the internal standards D 4 -cholate (D; green trace) and D 4 -deoxycholate (D; 
blue trace). (E-H) XIC chromatograms that illustrate the instrument Responses (counts per second (CPS) for taurocholate (E), 
cholate (F), deoxycholate (G), and the internal standards (H) for a 10 0 0-fold diluted bioreactor media sample. 
MS/MS acquisition method 
1. The TurboIonSpray R © electrospray ionization (ESI) probe is installed in the Turbo V TM ion source 
and is operated with the following source conditions: ionization mode polarity: negative; 
curtain gas (Cur): 20; TurboIonSpray TM voltage (IS): −4500 V; source temperature (TEM): 
250 °C; Ion Source Gas 1 (GS1; nebulization gas): 40; Ion Source Gas 2 (GS2; heater gas): 50. 
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Table 2 
Column efficiency characterization using a mid-level calibrator prepared at 62.5 ng/mL for all analytes and 250 ng/mL for all IS 
compounds. 
Analyte / IS MS/MS 
transition 
Column 
Length (L; 
cm) 
Retention 
Time ( τ R; 
min) 
Full width at 
half-max 
(W 1/2 ; mins) 
HETP 
(cm/plate) 
Plates per 
meter (N/m) 
CA 407 > 343 10 3.56 0.035 0.0 0 017 590,0 0 0 
D 4 –CA (IS) 411 > 347 10 3.56 0.031 0.0 0 014 720,0 0 0 
DCA 391 > 345 10 4.23 0.040 0.0 0 016 640,0 0 0 
D 4 -DCA (IS) 395 > 349 10 4.22 0.039 0.0 0 015 670,0 0 0 
TCA 514 > 124 10 3.04 0.031 0.0 0 019 520,0 0 0 
Table 3 
The molecule-specific MS parameters for cholic acid, deoxycholic acid, and taurocholic acid. 
Q1 ( m/z ) Q3 ( m/z ) Dwell Time (mS) ID Collision energy (CE) (V) 
407.3 343.3 50 Cholic acid 407 > 343 −47 
407.3 289.3 50 Cholic acid 407 > 289 −52 
411.3 347.3 50 Cholic acid-D4 411 > 347 −47 
411.3 290.3 50 Cholic acid-D4 411 > 290 −52 
391.3 345.3 50 Deoxycholic acid 391 > 345 −47 
391.3 355.3 50 Deoxycholic acid 391 > 355 −46 
395.3 349.3 50 Deoxycholic acid-D4 395 > 349 −47 
395.3 359.3 50 Deoxycholic acid-D4 395 > 359 −46 
514.3 124.1 50 Taurocholic acid 514 > 124 −64 
514.3 107.0 50 Taurocholic acid 514 > 107 −64 
2. MS operational parameters include the following: collisionally activated dissociation (CAD) gas 
pressure: “High”; declustering potential (DP): −40 V; entrance potential: −8 V; collision-cell 
exit potential (CXP): −10 V; mass analyzer quadrupole 1 (Q1) resolution setting: unit; Q3 
resolution: unit; molecule specific parameter for each bile acid analyte are tabulated in Table 3 . 
Method performance characteristics 
A total of four analytical batches were prepared across two separate days – each batch consisted 
of a calibration curve, 13 interspersed blanks, and 96 MBRA-derived media samples that had 
been diluted according to the procedures described above. Calibration curves were constructed for 
each analyte by plotting the instrument response (IR = A analyte / A IS ) factor of each Calibrator 
against their respective nominal concentration. From this plot, a least-squares, linear regression with 
weighting (1/x) was used to calculate the line of best fit for each analyte, and yielded the following 
representative calibration curves for each analyte: CA: IR CA = 0.00526 ∗[CA] + 0.00651, R 2 = 0.991; 
TCA: IR TCA = 2310 ∗[TCA] + 3045, R 2 = 0.9856; DCA: IR DCA = 0.00337 ∗[DCA] + 0.00641, R 2 = 0.999. 
Limit of Detection (LOD) and Limit of Quantitation (LOQ) estimates were calculated using the standard 
deviation of the y-intercepts and the mean slope of the four calibration curves calculated for each 
analyte as described previously [14] . The LOD and LOQ estimates for each analyte are tabulated with 
the mean linear regression parameters for the four calibration curves ( ± Standard Error of the Mean 
(SEM)) in Table 4 . 
Discussion 
Herein, we report on a high-throughput LC-MS/MS-based bioanalytical method that is suitable 
for the quantitation of CA, TCA, and DCA in microbiome relevant matrices such as stool and filter- 
sterilized MBRA-derived bioreactor broth media. Using this method, TCMC-MSL staff are capable of 
processing up to 192 stool or bioreactor samples in a single 8 h day, and the LC-MS/MS acquisition 
of all calibrators, blanks, and unknown samples will require ~36 h to complete for the two analytical 
batches. This method is highly adaptable, and with the purchase of authentic reference standards, can 
be modified to include other bile acids/salts that may be of interest TCMC-MSL collaborators. 
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Table 4 
Mean weighted (1/x) linear regression parameters for cholic acid (CA), taurocholic acid (TCA), and deoxycholic acid (DCA) 
calibration curves ( n = 4) over a dynamic range of 0.977 to 10 0 0 ng/mL. 
Analyte Internal Standard 
(IS) 
LOD / LOQ 
(ng/mL) 
Slope (mean ±
SEM) 
Y-intercept (mean 
± SEM) 
R 2 (mean ± SEM) 
CA D 4 –CA 0.20 / 0.63 0.00562 ± 1.8e −4 0.0 060 0 ± 1.8e −4 0.999 ± 1.8e −4 
TCA ∗ – 0.76 / 2.3 2410 ± 116 2800 ± 280 0.989 ± 1.3e −3 
DCA D 4 -DCA 1.1 / 3.4 0.00359 ± 1.2e −4 0.00359 ± 1.2e −4 0.999 ± 1.0e −4 
∗ A commercial source of D 4 -TCA Internal Standard reference material was not found during development. 
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